Clinical and laboratory characteristics of patients with monoclonal gammopathy of clinical significance
Medicinski podmladak · 2026 · 77 (1) · 70-76
DOI: 10.5937/mp77-65481 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicinski podmladak, 2026. Verfasst von Valentina Mlađenović und 2 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Monoclonal gammopathies of clinical significance (MGCS) are hematological disorders characterized by the presence of a pathological plasma cell or lymphoid clones, leading to organ damage without fulfilling criteria for malignant plasma cell proliferation.
Aim
This study aimed to analyze the clinical and laboratory characteristics of MGCS patients, and evaluate the impact of therapy on overall survival (OS) and progression-free survival (PFS). Material and methods: This retrospective analysis was conducted on 75 patients. Among them, 88% had monoclonal gammophaty of renal significance (MGRS). The MGNS was diagnosed in 10.7% of patients (POEMS syndrome 6.7%, DADS-M 1.3%, CIDP 2.7%), while one additional patient (1.3%) had monoclonal gammopathy of skin significance (MGSS, Schnitzler syndrome). Treatment included bortezomib-based chemotherapy (57.3%), alkylating agents (30.7%), lenalidomide (5.3%), daratumumab (5.3%), and rituximab (1.3%). High-dose chemotherapy with autologous stem cell transplantation (HDCT + ASCT) was performed in 21.3% of patients with AL amyloidosis and POEMS syndrome after induction.
Results
A therapeutic response was achieved in 72% of patients, with a median survival of 48 months. A renal response was observed in 65.6% of patients with MGRS, and all MGNS patients showed improvement. In the MGRS subgroup, 68.2% showed a favorable response: complete response in 16.7%, very good partial response in 16.7%, and partial response in 37.9%. Univariate analysis indicated that hematological response (p < 0.01), renal response (p < 0.01), and treatment with HDCT + ASCT (p = 0.03) significantly influenced survival. Multivariate analysis confirmed hematological response as significant for OS (p = 0.023). A deep hematological response was associated with longer survival.
Conclusion
Timely diagnosis and optimal therapy, aiming for a rapid and deep hematological response, are crucial for organ function preservation and improved patient survival.
Zitieren
APA
Mlađenović, V., Milovanović, B., & Bila, J. (2026). Clinical and laboratory characteristics of patients with monoclonal gammopathy of clinical significance. Medicinski podmladak, 77(1), 70-76. https://doi.org/10.5937/mp77-65481
Vancouver
Mlađenović V, Milovanović B, Bila J. Clinical and laboratory characteristics of patients with monoclonal gammopathy of clinical significance. Medicinski podmladak. 2026;77(1):70-76. doi:10.5937/mp77-65481
BibTeX
@article{Mlaenovi2026,
author = {Mlađenović, Valentina and Milovanović, Bogdan and Bila, Jelena},
title = {Clinical and laboratory characteristics of patients with monoclonal gammopathy of clinical significance},
journal = {Medicinski podmladak},
year = {2026},
volume = {77},
number = {1},
pages = {70--76},
doi = {10.5937/mp77-65481}
}
EUVIMED